Market News

NYSE:TEVA News

2 stories

Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea® (aflibercept), in Canada

TORONTO, Canada and INCHEON, South Korea, July 9, 2026 /CNW/ - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and Samsung Bioepis Co., Ltd. today announced that the companies have entered into a license and commercialization agreement for OPUVIZ® (aflibercept), a biosimilar referencing…

PR Newswire en
StocksCA